Risk of Neuroleptic Malignant Syndrome with Vesicular Monoamine Transporter Inhibitors

OBJECTIVE: Vesicular monoamine transporter-2 (VMAT2) inhibitors have been proven to be effective for the treatment of tardive dyskinesia and their use is likely to increase. The evidence base of published clinical reports was reviewed to evaluate the possible risk of neuroleptic malignant syndrome (...

Descripción completa

Detalles Bibliográficos
Autor principal: Caroff, Stanley N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean College of Neuropsychopharmacology 2020
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7242105/
https://www.ncbi.nlm.nih.gov/pubmed/32329312
http://dx.doi.org/10.9758/cpn.2020.18.2.322

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7242105/
https://www.ncbi.nlm.nih.gov/pubmed/32329312
http://dx.doi.org/10.9758/cpn.2020.18.2.322

Ejemplares similares